Certain that they are right, struggling to find ways to get their message across, public health officials are exasperated by their inability to convince more U.S. parents to vaccinate their children. They say they are contending with a small minority of parents who are misinformed about the risks of inoculations.
The makers of the nasal spray version of the flu vaccine say they now know why it didn't protect...
Personal or philosophical opposition to vaccines would not be an authorized exemption for the...
They're considered one of mankind's greatest medical achievements, yet people have balked at...
A new report shows this winter's nasty flu season has peaked and is clearly retreating. The flu reached its highest levels around the beginning of January, and stayed there for weeks. The government report out Friday shows flu has become less widespread and less intense in the last couple of weeks in most parts of the country.
It took 16 years of twists and turns. Over and over, Dr. Nancy Sullivan thought she was close to an Ebola vaccine, only to see the next experiment fail. "A case of resuscitation more than once," is how the National Institutes of Health researcher describes the journey.
The debate over whether parents should be required to get their children vaccinated against measles has created strange alliances, putting some liberal parents on the same side as Republican conservatives. While the two parties are not cleanly divided on the issue in the nation's state legislatures, it is increasingly the GOP that resists efforts to stiffen requirements on vaccinating kids.
Through an investigation of a fundamental process that guides the maturation of immune cells, researchers have revealed new insights into possible ways to vaccinate people to generate potent antibodies of the type that are predicted to offer protection against diverse strains of the highly mutable HIV.
Federal health officials are facing questioning about why this year's flu vaccine isn't giving good protection against the winter menace. This is a particularly bad flu season, and one reason is that the most common flu strain isn't a good match to this year's vaccine. Lawmakers on Tuesday asked why the Centers for Disease Control and Prevention didn't act months ago when concerns first arose to create a better-matched vaccine.
In their decades-long search for vaccines against drugs of abuse, scientists have hit upon a new approach to annul cocaine’s addictive buzz. They report in Molecular Pharmaceutics that their strategy, which they tested on mice, harnesses a bacterial protein to trigger an immune system attack on the drug if it enters the body. This response could dull cocaine’s psychotropic effects and potentially help users of the drug kick the habit.
As predicted, this year's flu vaccine is doing a pretty crummy job. It's only 23% effective, primarily because it doesn't include the bug that is making most people sick, according to a government study released today. That's one of the worst performances in the last decade, since U.S. health officials started routinely tracking how well vaccines work. In the best flu seasons, the vaccines were 50 to 60% effective.
Researchers at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows promise for targeting lung-specific diseases, such as influenza, pneumonia and tuberculosis.
The flu is now widespread in all but seven states, and hospitalization rates match the dismal season two years ago. While health officials fear this will be an unusually bad year, it's too soon to say. The latest figures released Monday by the CDC show the flu hitting hard in most of the 43 states where the illness was widespread. But the flu was not yet rampant in populous states like California and New York.
Vaccines designed to protect against HIV can backfire and lead to increased rates of infection. This unfortunate effect has been seen in more than one vaccine clinical trial. Scientists at Emory Univ. have newly published results that support a straightforward explanation for the backfire effect: vaccination may increase the number of immune cells that serve as viral targets.
HIV can be treated, but not every infection responds the same way. Treatment requires monitoring and testing, a practice that can become expensive for health care systems in the developing world.
As the health care industry is undergoing a rapid transformation driven by evolving economic and regulatory demands, the biopharmaceutical industry also faces numerous challenges in meeting the needs of patients around the globe. Emerging markets are faced with the challenges of ensuring access to innovative, personalized treatments for patients with critical or rare conditions.
Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects.
One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. Now, researchers have developed a non–surgical injection of programmable biomaterial to do so.
The flu vaccine may not be very effective this winter, according to U.S. health officials who worry this may lead to more serious illnesses and deaths. Flu season has begun to ramp up, and officials say the vaccine does not protect well against the dominant strain seen most commonly so far this year. That strain tends to cause more deaths and hospitalizations, especially in the elderly.
An experimental Ebola vaccine appears safe and triggered signs of immune protection in the first 20 volunteers to test it, U.S. researchers reported. The vaccine is designed to spur the immune system's production of anti-Ebola antibodies, and people developed them within four weeks of getting the shots at the National Institutes of Health.
A new hybrid vehicle is under development. Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies. The technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite much research, have yet to make a significant impact in the treatment of major illnesses.
The government proposed new rules Wednesday to make it easier for doctors and patients to learn if clinical trials of treatments worked or not. Thousands of Americans participate in clinical trials every year, testing new treatments, comparing old ones or helping to uncover general knowledge about health. Many of the studies are reported in scientific journals and trumpeted in the news.
Univ. of California, Los Angeles biochemists have created the largest-ever protein that self-assembles into a molecular “cage.” The research could lead to synthetic vaccines that protect people from the flu, HIV and other diseases. At a size hundreds of times smaller than a human cell, it also could lead to new methods of delivering pharmaceuticals inside of cells, or to the creation of new nanoscale materials.
A coalition of companies and aid groups announced plans Tuesday to test experimental drugs and collect blood plasma from Ebola survivors to treat new victims of the disease in West Africa. Plasma from survivors contains antibodies, substances the immune system makes to fight the virus.
Scientists at The Scripps Research Institute have identified weak spots on the surface of Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. The study provides a revealing 3-D picture of how the ZMapp antibodies bind to Ebola virus.
Health workers on the front line of the Ebola crisis say the need for urgent help isn't letting up, as Congress begins considering President Barack Obama's $6.2 billion emergency aid request to fight the disease. Despite reports that the number of infections is slowing in some parts of West Africa, cases still are rising in other areas.
A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a recent pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long lasting, which could have significant global implications in controlling future outbreaks.
European Union nations are working to reach 1 billion euros ($1.27 billion) in aid by the end of the week to fight Ebola in West Africa and are seeking a common approach to the crisis.EU foreign ministers began a week of talks Monday so their 28 leaders can agree by Friday on better measures to fight Ebola, anything from financial aid to common repatriation procedures, more Ebola treatment facilities and better training for health workers.
The new Urban Dynamics Institute at Oak Ridge National Laboratory is working with the Bill & Melinda Gates Foundation to aid polio vaccination efforts in developing countries. Teams at the institute will apply big data analysis to population dynamics in Nigeria, allowing polio vaccination crews to better estimate the amount of vaccine needed and to target areas of priority, saving time and money in eradicating the disease.
- Page 1